We have analyzed the transfusion requirements of a group of 132 peripheral blood stem cell transplants from a single institution (73 allografts and 59 autografts) over a 10-year period. The allografts were conducted using the 'Mexican' nonmyeloablative conditioning regimen, while the autografts were given single-day high-dose melphalan. For the allografts, the median number of transfused packed red blood (PRBC) cell units was 1 (range 0-22), while the median number of platelet transfusion (PLT) sessions was 1 (range 0-9); 45% of allografted individuals did not require PRBC transfusions and 35% did not require PLT. For autografts, the median number of PRBC units was 2 (range 0-21), while the median number of PLT was 2 (range 0-21); 33% of autografted individuals did not require PRBC and 25% did not require PLT. We conclude that, by using certain preparative regimens, both allo and auto hematopoietic stem cell grafts can be conducted without the transfusion of blood products. Bone Marrow Transplantation (2005) 36, 715-720.
The transfusional support of patients undergoing either autologous and allogeneic peripheral blood stem cell (PBSC) transplants is critical to the outcome of these patients. 1 We have been interested in simplifying PBSC transplant procedures in order to decrease costs and, accordingly, make them available to a larger number of individuals. In the case of autologous transplantation, by using a single-day conditioning regimen with high-dose melphalan, we have been able to conduct autografting without cryopreservation facilities, on an outpatient basis and with reduced costs. [2] [3] [4] In allografts, by using nonmyeloablative conditioning regimens, we have also been able to conduct the procedure fully on an outpatient basis and also with lower costs. [5] [6] [7] [8] [9] [10] [11] [12] Here, we report the results of the transfusion requirements of 132 patients undergoing PBSC transplants using simplified and previously described grafting methods.
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Materials and methods
Patients
All consecutive patients undergoing auto-or allogeneic PBSC-T in the Centro de Hematologı´a y Medicina Interna de Puebla since 1993 were accrued in the study. Informed consent to perform the grafts was obtained from all individuals, and their donors in the case of allografts. Table 1 shows patient characteristics.
Grafting procedures
Autografts. The method has been previously described: [2] [3] [4] briefly, subcutaneous G-CSF (5 mg/kg/day) was started on day À7 and given until granulocytes were greater than 5 Â 10 9 /l. Using either a peripheral vein or a Majurkar-type subclavian catheter, the apheresis procedures, on an outpatient basis, were performed on days À4, À3, and À2, using a Haemonetics V-50 PLUS machine (Haemonetics Corporation, Braintree, MA, USA) or a Baxter C-3000 PLUS machine (Baxter Healthcare, Deerfield, IL, USA) using the Spin-Nebraska protocol. 13 The end point of collection was processing 5000 ml of blood/m 2 in each of three apheresis procedures. The products of the apheresis and 1 ml aliquots were kept in ACD-A (Baxter Healthcare, Deerfield, IL, USA) at 41C, in 300 ml transfer packs (Baxter Healthcare, Deerfield, IL, USA) composed of gas impermeable, polyvinyl chloride plastic film. Conditioning with high-dose (200 mg/m 2 ) intravenous melphalan was used; ondansetron (1 mg i.v. every hour for 4 h after chemotherapy), ciprofloxacin (250 mg b.i.d.) and itraconazole (100 mg b.i.d.) were used in all patients. Antibiotics and antimycotics were used until granulocytes were greater than 0.5 Â 10 9 /l. The products of the PBSC apheresis performed on days À4, À3 and À2 were reinfused on an outpatient basis on days 0, þ 1 and þ 2, respectively. Patients had daily laboratory and clinical studies.
Allografts. The 'Mexican' nonmyeloablative conditioning regimen was used as previously described; 5,2-4,6-12 briefly, filgrastim (10 mg/kg/day) was delivered to the donors, in all cases HLA-identical siblings, on days À5 to þ 2. The apheresis procedures were performed on days 0, þ 1 and þ 2 by means of a Haemonetics V-50 PLUS machine 2 was delivered on days þ 1, þ 3, þ 5 and þ 11. Oral CyA was continued through day 180, with adjustments according to serum CyA levels; it was then tapered over 30-60 days. Ondansetron (1 mg intravenous every hour during 4 h after chemotherapy), ciprofloxacin (250 mg b.i.d.) and itraconazole (100 mg b.i.d.) were used in all patients; antibiotics and antimycotics were used until more than 500 granulocytes/ml were present. The products of the PBSC apheresis were infused as outpatients on days 0, 1 and 2.
Apheresis product studies
Enumeration of the total white blood, mononuclear (MNC) and CD34 positive cells was carried out by flow cytometry 14 in an EPICS Elite ESP apparatus (Coulter Electronics, Hialeah, FL, USA), using the HPCA-2 anti-CD34 monoclonal antibody 15 (Becton Dickinson, San Jose´, CA, USA).
Transfusion policy
Packed red blood cells (PRBC), 1.4 U/m 2 were transfused if significant clinical symptoms of anemia coexisted with hemoglobin levels below 12.5 g/dl, the normal range in Puebla, 2220 m above sea level; 16 the triggers were the symptoms (tacchycardia, dyspnea, dizziness, hypostenia, hipodinamia) and not the hemoglobin levels. Platelet concentrates (PLTC) transfusion sessions (4 concentrates/m 2 from multiple donors or one apheresis session from a single donor) were given every 48 h if the platelet count dropped below 10 Â 10 9 /l, or if bleeding symptoms were present with platelet counts between 10 and 20 Â 10 9 /l. PLTC transfusion sessions were given every 24 h in patients who, in addition of being thrombocytopenic, developed fever. In allografts, leucocyte-depleting filters were used and blood products were irradiated. The transfusion requirements were analyzed in the first 100 days after the grafts.
Results
Red blood cells transfusions
A total of 132 grafting procedures were analyzed. In 39 of 59 autografts (66%) and in 40 of 73 allografts patients (55%), PRBC were transfused; accordingly, approximately one of three grafted individuals was not transfused with red cells. In autografts, the median of transfused PRBC was 2 (range 0-21), whereas in allografts, the median was 1, range 0-9 (see Tables 1 and 2 ).
Platelet transfusions
In 44 of 59 autografts (75%) and in 47 of 73 allografts (64%), PLTC transfusions were employed; these data indicate that approximately one out of four grafted individuals did not require platelet transfusions. For autografts, the median number of PLTC transfusion sessions was 2 (range 0-21), whereas for allografts, the median was 1, with a range 0-9 (see Tables 1 and 2) .
Eight autografted (13%) and 21 allografted (28%) patients did not receive either RBC or PLTC transfusions. The median number of CD34 cells transfused was 5 (1.2-31) and 3 (1-64) Â 10 6 /kg, respectively, for allo and autografts. The correlation between the number of CD34 cells infused and platelet count recovery or red blood cells transfusion requirements was analyzed and was not statistically significantly different. It was interesting to note that patients with CML who were allografted were those that needed the least number of transfusions: Mean PRBC and PLT required were, respectively, 1 (range 0-5) and 1 (range 0-6), figures that contrast with those for patients with AML, in whom the mean PRBC number was 6 (range 0-18) and the mean PLT was 3 (range 0-9). These are not, however, statistically significant differences, probably due to the low number of patients in each subset. The low transfusion requirements of CML patients may be related to the decreased myeloablative therapy received by these individuals before the transplant, and to the lack of transfusions prior to the graft.
The association between the number of PRBC needed by the patients and the hemoglobin levels the day before the transplant was also analyzed (Table 3 ). There was a clear trend to transfuse less red blood cells in patients with higher hemoglobin levels; however, the differences are not significant for allografts (P ¼ 0.39) or for autografts (P ¼ 0.08). It was interesting to note that the median number of PRBC received by patients grafted with hemoglobin levels between 12 and 15 g/dl was 0 for allografts and 1 for autografts, while the PRBC requirements for individuals with less than 9 g/dl were 9.5 and 4, respectively, for allo and autografts.
Discussion
Hematopoietic stem cell transplantation has significantly evolved and simplification of the procedures has resulted in a substantial decrease in costs. 5, [2] [3] [4] [6] [7] [8] [9] [10] [11] [12] The possibility now exists to perform transplants entirely on an outpatient basis, 5 making them available to a larger number of patients, 5 an issue that is critical in developing countries. [17] [18] [19] We have shown that by using the simplified methods previously described, 5,2-4,6-12 and without compromising the efficacy of treatment for hematological malignancies, costs can be substantially lowered: autologous and allogeneic PBSC-T can be performed at median costs of 7500 and 18000 USD, 5,2-4,6-12 respectively, figures substantially lower than those described for conventional PBSC transplantation.
1 These costs cover the first 100 days after transplant and have been described previously.
5,2-4,6-12
The most important aspects of support therapy for patients undergoing PBSC transplantation are the management of infections and the provision of blood products. Using conventional PBSC transplantation programs, both auto-and allogeneic transplants require an average of 150 U of platelet concentrate and 15 U of PRBC; 20, 21 however, very recently, the possibility of conducting bone marrow auto-and allotransplants without transfusion of blood products has been described. [22] [23] [24] [25] [26] [27] [28] In a previous study, we showed in 44 patients allografted using the 'Mexican' nonmyeloablative conditioning regimen, that approximately one-third of the individuals did not require either red blood cell platelet transfusions, resulting in a decrease in both costs and risks stemming from exposure to human blood components. 24 We have now analyzed the transfusion requirements of a group of 132 individuals given autologous (59 procedures) allogeneic PBSC transplants (73 grafts), using the simplified methods, which have been previously described (2-12, vide supra). Our results confirm our previous observation in allografts and indicate that approximately one of 3-4 auto or allografts can be conducted without the transfusion of blood products. We also found a trend toward less use of red blood cells in individuals grafted with higher hemoglobin levels, as other authors have shown, 28 since there was a clear trend to transfuse less red blood cells in patients with higher hemoglobin levels; it was interesting that the median number of PRBC in patients grafted with hemoglobin levels between 12 and 15 g/dl was 0 for allografts and 1 for autografts, whereas the PRBC requirements for those individuals with less than 9 g/dl were 9.5 and 4, respectively, for allo and autografts.
In addition to diminishing both costs and risk of exposure to human blood derivatives, there are other reasons to consider performing bloodless transplants, including religious objections to blood products in Jehova's witnesses. 23 , 29 We did not engage in any procedure to diminish the blood derivatives requirements as other authors have carried out: Ballen et al 24 have shown that, by using human recombinant erythropoietin, G-CSF, iron salts and epsilon-amino-caproic acid, the transfusion requirements of autografted patients can be diminished substantially. 24 Other authors have also shown that transfusion requirements are reduced in individuals given nonablative preparative regimens for allogeneic stem cell transplantation. 28 Since one of our major obstacles for grafting is the cost of the procedure, 30 we elected not to engage in these blood products sparing actions; however, it is likely that, if we had done so, the proportion of bloodless grafted individuals could have been substantially increased. That the interest in conducting bone marrow transplantation without transfusions has grown in the last years is reflected by the fact that in the 2005 Tandem Bone Marrow Transplantation Meetings at Keystone, CO, USA, a workshop on the topic was conducted (Bloodless -transfusionfree -transplants: are you utilizing alternatives to minimize transfusions? February 11) .
In summary, we have found that simplification of procedures for autologous and allogeneic stem cell transplantation leads to the possibility of performing them without transfusions of platelets or red blood cells.
